Nervous Disorder TRIZ Cases

Segmenting aminoacyl-tRNA synthetases into functional fragments reveals non-canonical biological activities.

Fasting blood ammonia measurements guide nitrogen scavenging drug dosage adjustments to maintain target levels.

A pre-filled autoinjector stored in a light-blocking foil pouch allows immediate patient self-administration while preventing medication degradation.

N-aryl piperidine compounds selectively activate liver X receptor beta to treat neurodegenerative diseases without inducing peripheral lipid effects.

CNS-homing peptides resolve side effects by selectively targeting amyloid plaques in the entorhinal cortex, reducing neuroinflammation and cognitive decline.

Aqueous wet milling prevents brexpiprazole dihydrate anhydrate conversion during size reduction, preserving sustained release properties.

An apheresis device employs HTT binding molecules to capture and remove Huntingtin protein from blood plasma.

Exogenous targeting peptides inserted into the hypervariable region of AAV capsids enable blood-brain barrier crossing and deep brain cell transduction.

Modified stem cells introduce hepatocyte growth factor and neurogenin-1 to drive neuronal differentiation.

Prevotella copri probiotic strain regulates the gut-brain axis to improve hyperactive and impulsive behaviors in attention-deficit-hyperactivity disorder models.

Mavoglurant targets the mGluR5 receptor to treat substance use disorder, addressing the lack of FDA-approved medications for amphetamine addiction.

Combining cilostazol with carbostyril derivatives reduces Aβ deposition and manages behavioral symptoms.

Lactulose ferments in the colon to lower pH, trapping ammonia as ammonium ions and preventing neurotoxicity from antibiotic-induced gut issues.

Intravenous recombinant human NaGlu protein crosses the intact blood-brain barrier to treat central nervous system symptoms in Sanfilippo Syndrome B patients.

Segmented molecular design achieves selective B1 antagonism, reducing side effects from non-selective B2 blockade.

Alpha-ketoglutarate modulates enzyme activity to resolve the trade-off between energy production and oxidative stress reduction.

Quantum tunneling in Josephson devices enables direct collagen-1 detection without protein denaturation.

A ChIP-seq method maps CREB3L2-ATF4 DNA-binding profiles to identify retromer complex targets.

A mitochondrial composition restores cellular energy in seizure-genic brain regions to manage refractory epilepsy.

Aluminium oxyhydroxide slows cognitive decline progression by converting neurotoxic accumulation into disease-modifying therapy.

Synthetic peptide amides selectively activate kappa opioid receptors to modulate receptor activity.

PEG-modified alcohol dehydrogenase resists gastric pH and proteolytic degradation while oxidizing ethanol to acetaldehyde.

CLPTM1L-targeting agents bind the polypeptide to modulate survival signaling, overcoming tumor cell resistance to chemotherapeutics.

An enteric coating on activated carbon prevents nutrient adsorption in the stomach while maintaining adsorptive activity at the target site.

Measuring plasma PAA and PAGN levels calculates a ratio that adjusts HPN-100 dosages, preventing toxicity while maintaining nitrogen removal efficacy.

Atomizing agomelatine solution extends crystalline form V durability from six months to twenty-one months under standard storage conditions.

High semaglutide content in biodegradable microspheres reduces injection volume, minimizing pain and inflammatory responses while maintaining bioavailability.

Carborane compounds inhibit T-cell activation to reduce circulating levels, treating chronic heart failure post-myocardial infarction.

Controlled release SAMe compositions resolve trade-offs between therapeutic efficacy and pill burden by enabling once-daily dosing with reduced side effects.

Alpha7beta1 integrin modulatory agents increase receptor expression to enhance muscle regeneration and repair in dystrophic conditions.

Tetrahydrocannabivarin acts as a neutral antagonist at cannabinoid receptors to block activation without altering constitutive activity.

Antibodies target pathological phosphorylated tau epitopes to prevent tauopathy progression without interfering with normal tau function.

Combining fluoxetine with CLP290 activators improves pain relief efficacy while reducing adverse side effects from standard antidepressant therapies.

Intranasal suramin formulations use penetration enhancers to boost brain tissue concentrations while minimizing systemic toxicity.

Engineered antibodies target unique phosphorylated tau states to resolve the contradiction between general binding and precise pathological detection.

An enzyme agent converts dietary fructose to non-metabolizable 5-keto-D-fructose.

Specific Lactobacillus and Bifidobacterium strains trigger T cell apoptosis to restore Th1/Th2 balance without disrupting immune equilibrium.

Ependymal cells secrete ApoE ε2 into cerebrospinal fluid, bypassing the blood-brain barrier to reduce amyloid plaques.

Selective kappa opioid receptor antagonists reduce neuropathic pain and addiction behaviors without inducing tolerance or side effects.

Alkaline GSNO formulation with PVA prevents rapid decomposition, maintaining stable local vasodilation for diabetic ulcer treatment.

Pulsed electromagnetic energy stored in water improves balance and reduces pain, bypassing limited calcium supplementation.

Extracting pluripotent stem cells from dental pulp tissue using enzymatic digestion.

Pulsed electromagnetic fields stimulate neural tissue to enhance cellular activity and angiogenesis.

Anti-IL-6 receptor antibodies block signaling pathways to reduce pancreatic cancer cell migration and invasive capabilities.

Cationic lipid vectors form stable complexes with mRNA for central nervous system delivery.

Saffron extract containing safranal and crocin acts as a satiety agent to reduce hunger without the side effects of enzyme suppressant drugs.

Enzyme-mediated fucosylation increases stem cell homing efficiency, reducing the required dose for therapeutic engraftment.

Ofatumumab employs a structured dosing regimen to achieve B-cell depletion while maintaining safety in pediatric multiple sclerosis treatment.